Neuren Pharmaceuticals Limited
NURPF · OTC
Market closed$13.46$0.00 (0.00%)After hours $13.46 · 0.00%
Key statistics
Previous close$13.46
Open$12.00
Day high$13.46
Day low$12.00
52-week high$14.80
52-week low$7.70
Market cap1.71B
Volume250.00
Average volume40.00
P/E ratio86.64
Forward P/E—
EPS0.16
Dividend yield0.00%
Market context
Why it moved
NURPF's price remained flat today with no significant news or catalysts directly tied to the stock, as trading volume was minimal and the price held steady at its previous close level.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 15, 2026How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population EstimateSimply Wall Street · July 2, 2026Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?Moomoo · June 30, 2026Neuren Pharmaceuticals's Earnings Boosted by EU U-Turn on Trofinetide -- Market TalkMoomoo · June 29, 2026Neuren Pharmaceuticals Price Target Raised 6.8% to A$23.50/Share by Bell Potter Mt Newswire · June 29, 2026Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline Mt Newswire · June 29, 2026Update: Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee; Shares Up 29% Mt Newswire · June 28, 2026Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee Mt Newswire · May 7, 2026Neuren Pharmaceuticals' Nasdaq-Listed Partner Reports 20% Increase in Q1 Net Sales of Rett Syndrome Drug; Shares Up 3% Mt Newswire · April 8, 2026Neuren Pharmaceuticals Says Rett Syndrome Drug DAYBUE STIX Widely Available in the US Mt Newswire · March 2, 2026Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application Mt Newswire · February 27, 2026Neuren Pharmaceuticals Posts Lower 2025 Earnings, Revenue Mt Newswire · February 26, 2026Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%